Stock Events

Stock Events

SELLAS Life Sciences Group 

$7.73
344
-$0.10-1.28% Monday 20:00

Statistics

Day High
8.12
Day Low
7.53
52W High
9.51
52W Low
1.39
Volume
5,791,240
Avg. Volume
-
Mkt Cap
1.1B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Apr 11
$12.02
Dec 10
$21.07
Sep 10
$7.50
Jun 10
$4.25
Mar 10
$4.25
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

6AugExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Next
-0.13
-0.1
-0.08
-0.05
Expected EPS
-0.05
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-61.76MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow SLS. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap292.07B
Novartis is a large pharmaceutical company with a broad oncology portfolio, including cancer vaccines and immunotherapies, competing on a larger scale with SELLAS.
Merck
MRK
Mkt Cap294.03B
Merck & Co., Inc. has a strong presence in the cancer immunotherapy market with products like Keytruda, competing with SELLAS's cancer treatments.
Bristol-Myers Squibb
BMY
Mkt Cap116.66B
Bristol-Myers Squibb Company offers a range of cancer immunotherapies, making it a competitor to SELLAS in the oncology market.
Pfizer
PFE
Mkt Cap149.38B
Pfizer Inc. has a diversified portfolio that includes oncology products, competing with SELLAS in the development and marketing of cancer treatments.
AMGEN
AMGN
Mkt Cap191.7B
Amgen Inc. is involved in the discovery and development of innovative human therapeutics, including cancer treatments, competing with SELLAS's focus areas.
Astrazeneca
AZN
Mkt Cap277.22B
AstraZeneca PLC has a strong oncology unit that develops cancer immunotherapies, making it a competitor to SELLAS in the global oncology market.

About

SELLAS Life Sciences Group, Inc. operates as a late-stage biopharmaceutical entity, dedicated to advancing novel cancer immunotherapies for various cancer indications across the United States. Its primary investigational product, galinpepimut-S (GPS), is a cancer immunotherapeutic agent engineered to target Wilms tumor 1. GPS is currently in Phase III clinical trials for acute myeloid leukemia and Phase 1/2 studies for ovarian cancer. Additionally, the company is progressing nelipepimut-S, an immunotherapy aimed at human epidermal growth factor receptor 2, which is undergoing Phase 2b clinical evaluation for early-stage breast cancer. A strategic collaboration with Merck & Co., Inc. is underway to assess GPS in combination with the PD1 blocker pembrolizumab, specifically within a Phase 1/2 clinical trial encompassing up to five distinct cancer indications, including both hematologic malignancies and solid tumors. Founded in 2012, SELLAS maintains its corporate headquarters in New York, New York.
Show more...
CEO
Dr. Angelos M. Stergiou M.D., ScD h.c.
Employees
15
Country
United States
ISIN
US81642T2096

Listings

MU
DE
RXK3.MU
XNAS
US
SLS
STU
DE
RXK3.STU
BOATS
BOATS
SLS.BOATS

0 Comments

Share your thoughts

FAQ

What is SELLAS Life Sciences Group stock price today?▼
The current price of SLS is $7.73 USD — it has decreased by -1.28% in the past 24 hours. Watch SELLAS Life Sciences Group stock price performance more closely on the chart.
What is SELLAS Life Sciences Group stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange SELLAS Life Sciences Group stocks are traded under the ticker SLS.
Is SELLAS Life Sciences Group stock price growing?▼
SLS stock has risen by +0.65% compared to the previous week, the month change is a +9.18% rise, over the last year SELLAS Life Sciences Group has showed a +380.12% increase.
What is SELLAS Life Sciences Group market cap?▼
Today SELLAS Life Sciences Group has the market capitalization of 1.1B
When is the next SELLAS Life Sciences Group earnings date?▼
SELLAS Life Sciences Group is going to release the next earnings report on August 06, 2026.
What were SELLAS Life Sciences Group earnings last quarter?▼
SLS earnings for the last quarter are -0.05 USD per share, whereas the estimation was -0.06 USD resulting in a +16.67% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is SELLAS Life Sciences Group revenue for the last year?▼
SELLAS Life Sciences Group revenue for the last year amounts to 0 USD.
What is SELLAS Life Sciences Group net income for the last year?▼
SLS net income for the last year is -61.76M USD.
Does SELLAS Life Sciences Group pay dividends?▼
Yes, SLS dividends are paid quarterly. The last dividend per share was 12.02 USD. As of today, Dividend Yield (FWD)% is 0%.
How many employees does SELLAS Life Sciences Group have?▼
As of June 16, 2026, the company has 15 employees.
In which sector is SELLAS Life Sciences Group located?▼
SELLAS Life Sciences Group operates in the Health & Wellness sector.
When did SELLAS Life Sciences Group complete a stock split?▼
The last stock split for SELLAS Life Sciences Group was on November 08, 2019 with a ratio of 1:50.
Where is SELLAS Life Sciences Group headquartered?▼
SELLAS Life Sciences Group is headquartered in New York, United States.